Safety and Efficacy Assessment of Using the zLOCK Facet Stabilization System
1 other identifier
interventional
80
2 countries
2
Brief Summary
The zLOCK Facet Stabilization System is a fixation device intended to provide posterior stability in the lumbar spine fusion procedure. The system can be placed either as an adjunct to an inter-vertebral anterior cage or as stand-alone with/ without additional decompression of the dural sac or nerve roots as appropriate for the specific patient and surgeon's discretion. The zLOCK implant is placed inside the facet to stabilize the motion and enhance the bony fusion of the joint. The zLOCK Facet Stabilization System is intended for single-level stabilization of a spinal motion segment in order to promote bony fusion of the joint. The zLOCK system is indicated for use from L1-L2 to L5-S1 joints. The zLOCK implant is inserted into the facet joint space while adapting to the joint's changing geometry. Stabilization is achieved by a firm grip of each joint bone and resisting any relative motion. The zLOCK implant is placed percutaneously and requires only one incision per side, thereby reducing the invasiveness procedure duration and shortening the recovery period. This pivotal study was designed in order to assess the safety and effectiveness of the zLOCK system.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable low-back-pain
Started Nov 2021
Longer than P75 for not_applicable low-back-pain
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 7, 2021
CompletedFirst Submitted
Initial submission to the registry
February 13, 2022
CompletedFirst Posted
Study publicly available on registry
March 4, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2025
CompletedFebruary 7, 2024
February 1, 2024
3.2 years
February 13, 2022
February 6, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of Treatment-Emergent Adverse Events as assessed by paucity of device related reoperation
The safety of the zLOCK Facet Implant System will be established based on the paucity of device-related reoperations.
3 months
Secondary Outcomes (1)
Change in pain level measured by Visual Analog Score for pain
1 year
Study Arms (1)
zLock Facet Locking Implant System
EXPERIMENTALDevice: zLOCK Facet Stabilization System zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
Interventions
zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
Eligibility Criteria
You may qualify if:
- Patient is scheduled for spine surgery with at least one of the following:
- Degenerative Spondylolisthesis grade 1;
- Mild to Moderate stenosis;
- Degeneration of the facets.
- When used stand-alone disc height should be maximum 50% of the adjacent disc height.
- \< Age \<75
- Weight \< 100Kg
- Signed informed consent form
- At least 3 months of unsuccessful conventional treatments
You may not qualify if:
- Fusion procedure performed or required in more than one motion segment.
- Acute or chronic spinal infections.
- Osteoporosis when used in adjunct to an anterior interbody cage (DEXA \< -2.5).
- Absence of posterior spinal elements including the pedicle, pars interarticularis, facet joints, spinous process and the majority of the lamina which make it unstable or not possible to place.
- Any entity or conditions that totally preclude the possibility of fusion, i.e. cancer or kidney dialysis.
- Obesity (BMI ≥30)
- Unilateral application of device, except in combination with anterior interbody cages.
- Known sensitivity to Titanium.
- Alcoholism, or drug abuse
- Subject with a cardiac pacemaker or other implanted electro medical device
- Women who are either pregnant or nursing at the time of screening (to be verified by test in case of woman of child-bearing potential that do not practice medically acceptable methods of contraception)
- Concurrent participation in another clinical trial using any investigational drug or device.
- Mental disorders.
- Tumor
- Fracture or other instabilities of the posterior elements.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ZygoFixlead
Study Sites (2)
MedizinischenFakultät der Universität Rostock
Rostock, 18055, Germany
AOU Policlinico "Paolo Giaccone"
Palermo, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Hanna Levy, Dr.
ZygoFix
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 13, 2022
First Posted
March 4, 2022
Study Start
November 7, 2021
Primary Completion
January 30, 2025
Study Completion
September 30, 2025
Last Updated
February 7, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share